Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation

Frontiers in Genetics

Volumn 4, Issue DEC, 2013, Pages

  Kikuchi, Yasuko ^a,b   Tsuji, Eiichi ^b   Yagi, Koichi ^a   Matsusaka, Keisuke ^b   Tsuji, Shingo ^a   Kurebayashi, Junichi ^c   Ogawa, Toshihisa ^b   Aburatani, Hiroyuki ^a   Kaneda, Atsushi ^a,d,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

BRAF; CIMP (CpG island methylator phenotype); DNA methylation; Oncogene mutation; RAS; Thyroid cancer

Indexed keywords

EID: 84892424303     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2013.00271     Document Type: Article

References (53)

1. Baak, U., Gokbuget, N., Orawa, H., Schwartz, S., Hoelzer, D., Thiel, E., et al. (2008). Thymic adult T-cell acute lymphoblastic leukemia stratified in standard-and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group. Leukemia 22, 1154-1160. doi: 10.1038/leu.2008.52.
2. Baylin, S. B., and Ohm, J. E. (2006). Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction. Nat. Rev. Cancer 6, 107-116. doi: 10.1038/nrc1799.
3. Burwinkel, B., Rootwelt, T., Kvittingen, E. A., Chakraborty, P. K., and Kilimann, M. W. (2003). Severe phenotype of phosphorylase kinase-deficient liver glycogenosis with mutations in the PHKG2 gene. Pediatr. Res. 54, 834-839. doi: 10.1203/01.PDR.0000088069.09275.10.
4. Clement-Jones, M., Schiller, S., Rao, E., Blaschke, R. J., Zuniga, A., Zeller, R., et al. (2000). The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum. Mol. Genet. 9, 695-702. doi: 10.1093/hmg/9.5.695.
5. Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., et al. (2003). BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95, 625-627. doi: 10.1093/jnci/95.8.625.
6. Dean, D. S., and Hay, I. D. (2000). Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 7, 229-239.
7. Esteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286-298. doi: 10.1038/nrg2005.
8. Ezaki, H., Ebihara, S., Fujimoto, Y., Iida, F., Ito, K., Kuma, K., et al. (1992). Analysis of thyroid carcinoma based on material registered in Japan during 1977-1986 with special reference to predominance of papillary type. Cancer 70, 808-814. doi: 10.1002/1097-0142(19920815)70:4<808::AID-CNCR2820700415>3.0.CO;2-L.
9. Feinberg, A. P., Ohlsson, R., and Henikoff, S. (2006). The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7, 21-33. doi: 10.1038/nrg1748.
10. Guan, H., Ji, M., Hou, P., Liu, Z., Wang, C., Shan, Z., et al. (2008). Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer 113, 247-255. doi: 10.1002/cncr.23548.
11. Hay, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R., and Grant, C. S. (1993). Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114, 1050-1057. discussion: 7-8.
12. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U.S.A. 93, 9821-9826. doi: 10.1073/pnas.93.18.9821.
13. Hinoue, T., Weisenberger, D. J., Lange, C. P., Shen, H., Byun, H. M., Van Den Berg, D., et al. (2012). Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22, 271-282. doi: 10.1101/gr.117523.110.
14. Hoque, M. O., Rosenbaum, E., Westra, W. H., Xing, M., Ladenson, P., Zeiger, M. A., et al. (2005). Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J. Clin. Endocrinol. Metab. 90, 4011-4018. doi: 10.1210/jc.2005-0313.
15. Ishizaka, Y., Itoh, F., Tahira, T., Ikeda, I., Ogura, T., Sugimura, T., et al. (1989). Presence of aberrant transcripts of ret proto-oncogene in a human papillary thyroid carcinoma cell line. Jpn. J. Cancer Res. 80, 1149-1152. doi: 10.1111/j.1349-7006.1989.tb01645.x.
16. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., et al. (2005). Cancer statistics, 2005. CA. Cancer J. Clin. 55, 10-30. doi: 10.3322/canjclin.55.1.10.
17. Joo, J. Y., Park, J. Y., Yoon, Y. H., Choi, B., Kim, J. M., Jo, Y. S., et al. (2012). Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J. Clin. Endocrinol. Metab. 97, 3996-4003. doi: 10.1210/jc.2012-2444.
18. Kaneda, A., Kaminishi, M., Yanagihara, K., Sugimura, T., and Ushijima, T. (2002). Identification of silencing of nine genes in human gastric cancers. Cancer Res. 62, 6645-6650.
19. Kaneda, A., and Yagi, K. (2011). Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Cancer Sci. 102, 18-24. doi: 10.1111/j.1349-7006.2010.01712.x.
20. Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., and Fagin, J. A. (2003). High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457.
21. Knauf, J. A., and Fagin, J. A. (2009). Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr. Opin. Cell Biol. 21, 296-303. doi: 10.1016/j.ceb.2009.01.013.
22. Kondo, T., Nakazawa, T., Murata, S., Kurebayashi, J., Ezzat, S., Asa, S. L., et al. (2007). Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum. Pathol. 38, 1810-1818. doi: 10.1016/j.humpath.2007.04.014.
23. Kurebayashi, J., Okubo, S., Yamamoto, Y., Ikeda, M., Tanaka, K., Otsuki, T., et al. (2006). Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother. Pharmacol. 58, 460-470. doi: 10.1007/s00280-006-0185-x.
24. Kurebayashi, J., Tanaka, K., Otsuki, T., Moriya, T., Kunisue, H., Uno, M., et al. (2000). All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J. Clin. Endocrinol. Metab. 85, 2889-2896. doi: 10.1210/jc.85.8.2889.
25. La Celle, P. T., and Polakowska, R. R. (2001). Human homeobox HOXA7 regulates keratinocyte transglutaminase type 1 and inhibits differentiation. J. Biol. Chem. 276, 32844-32853. doi: 10.1074/jbc.M104598200.
26. Lee, K. C., Li, C., Schneider, E. B., Wang, Y., Somervell, H., Krafft, M., et al. (2012). Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer. Surgery 152, 977-983. doi: 10.1016/j.surg.2012.08.019.
27. Loh, K. C., Greenspan, F. S., Gee, L., Miller, T. R., and Yeo, P. P. (1997). Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metab. 82, 3553-3562. doi: 10.1210/jc.82.11.3553.
28. Matsusaka, K., Kaneda, A., Nagae, G., Ushiku, T., Kikuchi, Y., Hino, R., et al. (2011). Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 71, 7187-7197. doi: 10.1158/0008-5472.CAN-11-1349.
29. McLeod, D. S., Sawka, A. M., and Cooper, D. S. (2013). Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet 381, 1046-1057. doi: 10.1016/S0140-6736(12)62205-3.
30. Mitsutake, N., Miyagishi, M., Mitsutake, S., Akeno, N., Mesa, C. Jr., Knauf, J. A., et al. (2006). BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147, 1014-1019. doi: 10.1210/en.2005-0280.
31. Mohammadi-asl, J., Larijani, B., Khorgami, Z., Tavangar, S. M., Haghpanah, V., Kheirollahi, M., et al. (2011). Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARbeta2 genes in papillary thyroid carcinoma. Med. Oncol. 28, 1123-1128. doi: 10.1007/s12032-010-9587-z.
32. Nagae, G., Isagawa, T., Shiraki, N., Fujita, T., Yamamoto, S., Tsutsumi, S., et al. (2011). Tissue-specific demethylation in CpG-poor promoters during cellular differentiation. Hum. Mol. Genet. 20, 2710-2721. doi: 10.1093/hmg/ddr170.
33. Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., et al. (2003). Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 88, 4393-4397. doi: 10.1210/jc.2003-030305.
34. Noguchi, S., Murakami, N., and Kawamoto, H. (1994). Classification of papillary cancer of the thyroid based on prognosis. World J. Surg. 18, 552-7. discussion: 8. doi: 10.1007/BF00353763.
35. Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522. doi: 10.1016/j.ccr.2010.03.017.
36. Piccardo, A., Arecco, F., Puntoni, M., Foppiani, L., Cabria, M., Corvisieri, S., et al. (2013). Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin. Nucl. Med. 38, 18-24. doi: 10.1097/RLU.0b013e318266d4d8.
37. Schmidt, B., Liebenberg, V., Dietrich, D., Schlegel, T., Kneip, C., Seegebarth, A., et al. (2010). SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 10:600. doi: 10.1186/1471-2407-10-600.
38. Shaha, A. R., Shah, J. P., and Loree, T. R. (1996). Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann. Surg. Oncol. 3, 534-538. doi: 10.1007/BF02306085.
39. Shen, L., Toyota, M., Kondo, Y., Lin, E., Zhang, L., Guo, Y., et al. (2007). Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. U.S.A. 104, 18654-18659. doi: 10.1073/pnas.0704652104.
40. Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M., Weijenberg, M. P., et al. (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31, 141-149. doi: 10.1038/ng892.
41. Tada, Y., Yokomizo, A., Shiota, M., Tsunoda, T., Plass, C., and Naito, S. (2011). Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer. Int. J. Oncol. 39, 727-733. doi: 10.3892/ijo.2011.1049.
42. Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., and Issa, J. P. (1999). CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 96, 8681-8686. doi: 10.1073/pnas.96.15.8681.
43. Ulisse, S., Baldini, E., Sorrenti, S., Barollo, S., Prinzi, N., Catania, A., et al. (2012). In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin. Endocrinol. (Oxf.) 77, 780-786. doi: 10.1111/j.1365-2265.2012.04465.x.
44. Vogel, N., Schiebel, K., and Humeny, A. (2009). Technologies in the whole-genome age: MALDI-TOF-based genotyping. Transfus. Med. Hemother. 36, 253-262. doi: 10.1159/000225089.
45. Weber, M., Hellmann, I., Stadler, M. B., Ramos, L., Paabo, S., Rebhan, M., et al. (2007). Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39, 457-466. doi: 10.1038/ng1990.
46. Weishaupt, J. H., Klocker, N., and Bahr, M. (2005). Axotomy-induced early down-regulation of POU-IV class transcription factors Brn-3a and Brn-3b in retinal ganglion cells. J. Mol. Neurosci. 26, 17-25. doi: 10.1385/JMN:26:1:017.
47. Xing, M., Cohen, Y., Mambo, E., Tallini, G., Udelsman, R., Ladenson, P. W., et al. (2004). Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 64, 1664-1668. doi: 10.1158/0008-5472.CAN-03-3242.
48. Xing, M., Haugen, B. R., and Schlumberger, M. (2013). Progress in molecular-based management of differentiated thyroid cancer. Lancet 381, 1058-1069. doi: 10.1016/S0140-6736(13)60109-9.
49. Xing, M., Usadel, H., Cohen, Y., Tokumaru, Y., Guo, Z., Westra, W. B., et al. (2003). Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res. 63, 2316-2321.
50. Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., et al. (2005). BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 6373-6379. doi: 10.1210/jc.2005-0987.
51. Yagi, K., Akagi, K., Hayashi, H., Nagae, G., Tsuji, S., Isagawa, T., et al. (2010). Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 16, 21-33. doi: 10.1158/1078-0432.CCR-09-2006.
52. Yagi, K., Takahashi, H., Akagi, K., Matsusaka, K., Seto, Y., Aburatani, H., et al. (2012). Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. Am. J. Pathol. 180, 616-625. doi: 10.1016/j.ajpath.2011.10.010.
53. Yamashita, H., Noguchi, S., Murakami, N., Watanabe, S., Uchino, S., Kawamoto, H., et al. (1998). Changing trends and prognoses for patients with papillary thyroid cancer. Arch. Surg. 133, 1058-1065. doi: 10.1001/archsurg.133.10.1058.